VistaGen Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€557.52K - Cost of goods sold
€423.75K - Gross profit
€272.72K - SG&A expenses
€14.57M - R&D expenses
€37.46M - EBITDA
-€50.44M - D&A
€424.61K - EBIT
-€51.48M - Interest expenses
€0.00 - EBT
-€48.13M - Tax expenses
€6.04K - Net income
-€48.14M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€424.61K - Changes in working capital
€1.27M - Operating cash flow
-€43.22M - Capex
€39.70K - Other investing cash flow
-€88.89K - Net investing cash flow
-€7.31M - Total cash dividends paid
€0.00 - Issuance of common stock
€3.00M - Debt repayment
€802.62K - Other financing cash flow
€173.47K - Net financing cash flow
€3.98M - Foreign exchange effects
€0.00 - Net change in cash
-€46.55M - Cash at end of period
€42.28M - Free cash flow
-€43.18M
Balance sheet
- Cash and cash equivalents
€42.28M - Cash and short-term investments
€54.53M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.05M - Total current assets
€57.58M - Property, plant & equipment
€1.50M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€407.35K - Total non-current assets
€1.91M - Total assets
€59.48M - Accounts payable
€419.44K - Short-term debt
€1.36M - Other current liabilities
€5.68M - Total current liabilities
€9.63M - Long-term debt
€675.76K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€866.49K - Total liabilities
€10.49M - Common stock
€25.03K - Retained earnings
-€364.83M - Other equity
€863.04 - Total equity
€48.99M - Total liabilities and shareholders' equity
€59.48M
Company information
- Market capitalization
€48.99M - Employees
48 - Enterprise Value
-€4.89M
Company ratios
- Gross margin
-
48.9% Much better than peer group: -11,636,933,016,064,995.0% - EBITDA margin
-
-9,047.2% Much better than peer group: -13,127,519,757,363,565,000.0% - EBIT margin
-
-9,233.1% Much better than peer group: -13,302,592,807,210,067,000.0% - EBT margin
-
-8,633.6% Much better than peer group: -16,119,049,673,895,640,000.0% - Net margin
-
-8,634.7% Much better than peer group: -12,359,170,992,121,736,000.0% - ROE
-
-98.3% Much worse than peer group: -20.3% - ROA
-
-80.9% Much better than peer group: -106.2% - Asset turnover
-
0.9% Much worse than peer group: 40.6% - FCF margin
-
-7,758.5% Much better than peer group: -2,627,575,238,259,639,600.0% - FCF yield
-88.3% - Efficiency ratio
9,147.2% - Net sales per employee
-
€11.62K - Net income per employee
-
-€1.00M